STEP 5: The Definitive Two-Year Trial

STEP 5 was specifically designed to evaluate Wegovy over a full 2-year (104-week) period:

• Participants: 304 adults with BMI of 30+ (or 27+ with a weight-related condition)
• Weight loss at 104 weeks: 15.2% of body weight on Wegovy versus 2.6% on placebo .
• Absolute loss: Approximately 35 pounds from an average starting weight of 233 pounds.
• 20%+ responders: About 36% of participants lost 20% or more of their body weight, even at 2 years.
• Weight trajectory: Peak weight loss occurred around week 60 to 68 (approximately 15 months). A very small amount of regain (1% to 2%) occurred between peak and week 104, but overall results were well-maintained.

STEP 5 confirmed that Wegovy delivers sustained, clinically meaningful weight loss over 2 years of continuous treatment.

Cardiovascular Protection: The SELECT Trial

Beyond weight loss, Wegovy made medical history with the SELECT cardiovascular outcomes trial:

• 17,604 participants with obesity and established cardiovascular disease (no diabetes requirement)
• 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) with semaglutide 2.4 mg versus placebo .
• Median follow-up: 40 months (more than 3 years), with some participants followed for up to 5 years.
• This led to an expanded FDA indication for Wegovy to reduce cardiovascular risk in patients with obesity and heart disease .

At the 2-year mark, patients with cardiovascular risk factors are benefiting from both the weight management and the direct cardioprotective effects of Wegovy.

Two-Year Timeline

• Months 1 to 4 (titration to 2.4 mg): Five-step dose escalation. Weight loss of 5 to 12 pounds. GI side effects peak during this phase. Appetite suppression develops progressively.
• Months 5 to 9 (active loss at full dose): Fastest weight loss period. Cumulative loss of 18 to 30 pounds. Noticeable changes in body shape, clothing fit, and energy levels.
• Months 10 to 15 (maximum loss): Weight loss peaks. Cumulative loss of 28 to 38 pounds. Lab work shows significant improvements in metabolic markers.
• Months 16 to 20 (stabilization): Weight plateaus with minor fluctuations. Cumulative loss sustained at 30 to 38 pounds. Side effects are minimal.
• Months 21 to 24 (maintenance): Weight remains within 2 to 4 pounds of maximum loss. Total sustained loss of 28 to 38+ pounds. Cardiovascular and metabolic benefits continue to accrue.

What Happens During Year Two

Year two on Wegovy is a maintenance year for most patients. Here is what to expect:

• Minimal additional weight loss: Most of the weight loss happens in year one. Year two is about holding those gains, which is itself a significant achievement.
• Continued metabolic improvement: Some lab values continue to improve gradually during year two, even without further weight loss.
• Stable side effect profile: GI issues are rare by year two. The most common complaints are mild constipation and occasional fatigue.
• Psychological adaptation: Many patients describe fully adjusting to their new body and eating patterns during year two. Some find this transition more challenging than expected and benefit from counseling or support groups.
• Lifestyle habit consolidation: The healthier behaviors developed during year one become more automatic and deeply ingrained.

Managing Long-Term Wegovy Treatment

• Continue your injections consistently: Even if your weight is stable, the medication is actively preventing regain. Do not stop without discussing with your provider.
• Prioritize muscle preservation: After 2 years of weight loss, lean mass preservation is critical. Resistance training 3 times per week and protein intake of at least 1.0 g/kg body weight daily.
• Monitor for nutritional deficiencies: Extended reduced appetite can lead to inadequate intake of B12, iron, calcium, vitamin D, and other micronutrients. Annual blood work should include these markers.
• Discuss dose adjustments: Some providers explore reducing from 2.4 mg to 1.7 mg for stable maintenance patients. Any change should be gradual and monitored for weight rebound.
• Consider long-term cost planning: Budgeting for ongoing treatment is important. Explore insurance optimization, manufacturer programs, or compounded semaglutide alternatives if cost is a barrier $1,300-$1,400/mo (brand).

Frequently Asked Questions

Does Wegovy keep working after 2 years?

Yes. Wegovy continues to suppress appetite and maintain weight loss. The STEP 5 data shows sustained efficacy at 104 weeks, and the SELECT trial provides safety and efficacy data through 5 years. The medication does not lose its effect over time .

Is a slight weight regain in year two normal?

Yes. STEP 5 showed approximately 1% to 2% of body weight regain between the weight loss nadir (around month 15) and the 2-year mark. This is a normal physiological adjustment and is far less than the regain seen without medication .

Should I switch to Zepbound for more weight loss?

If you have plateaued on Wegovy and want additional weight loss, Zepbound (tirzepatide) is a reasonable option to discuss with your provider. Tirzepatide produces approximately 5% to 7% more body weight loss in clinical trials. However, Wegovy has the advantage of proven cardiovascular outcomes data.

What happens if supply issues interrupt my treatment?

Temporary supply interruptions have affected Wegovy at various points. If you cannot get your medication, contact your provider immediately. Options include temporary use of lower-dose pens, switching to Ozempic at available doses, or using compounded semaglutide as a bridge. Even short gaps can lead to some weight regain, so proactive planning is important.

Can I take Wegovy for 5 or more years?

The SELECT trial provides safety and cardiovascular benefit data through 5 years. There is currently no evidence suggesting a maximum safe duration of use. Wegovy, like blood pressure medication, is designed for long-term chronic disease management .

Protect Your Two-Year Investment

Two years on Wegovy represents a major commitment to your health. The clinical evidence confirms that the benefits are real, substantial, and sustained with continued treatment. To keep your results and plan wisely for the years ahead, partner with a provider who specializes in long-term GLP-1 management.

Connect with a FormBlends provider to review your progress and plan your ongoing treatment.